



Investor presentation

Second quarter and half year of 2026 results

An extract from parent company's, Georgia capital PLC, results file while for the full version they can refer to the following link: [Financial Results | Georgia Capital](#)

FORWARD LOOKING STATEMENTS



This announcement contains forward-looking statements, including, but not limited to, statements concerning expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, competitive strengths and weaknesses, plans or goals relating to financial position and future operations and development. Although Georgia Capital PLC believes that the expectations and opinions reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations and opinions will prove to have been correct. By their nature, these forward-looking statements are subject to a number of known and unknown risks, uncertainties and contingencies, and actual results and events could differ materially from those currently being anticipated as reflected in such statements. Important factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements, certain of which are beyond our control, regional instability; regulatory risk across a wide range of industries; investment risk; liquidity risk; portfolio company strategic and execution risks; currency fluctuations, including depreciation of the Georgian Lari, and macroeconomic risk; and other key factors that could adversely affect our business and financial performance, which are contained elsewhere in this document and in our past and future filings and reports and also the 'Principal Risks and Uncertainties' included in the 1H21 Result Announcement and in Georgia Capital PLC's Annual Report and Accounts 2020. No part of this document constitutes, or shall be taken to constitute, an invitation or inducement to invest in Georgia Capital PLC or any other entity, and must not be relied upon in any way in connection with any investment decision. Georgia Capital PLC and other entities undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required. Nothing in this document should be construed as a profit forecast.

HEALTHCARE SERVICES BUSINESS OVERVIEW



HEALTHCARE BUSINESS PORTFOLIO

MARCH 2026

37
Hospitals

16
Polyclinics


1
Laboratory

KEY UPDATES:

- ✓ OPENED TWO NEW CATH LABS DURING THE QUARTER
- ✓ APPOINTED A NEW CEO FOR REGIONAL AND COMMUNITY HOSPITALS
- ✓ EXPANDED SERVICE OFFERINGS ACROSS THE REGIONS
- ✓ LAUNCHED FIVE NEW LAB RETAIL BRANCHES
- ✓ IMPROVED NET DEBT TO LTM EBITDA FROM 4.1 TO 3.7 Y-O-Y (AS OF MARCH 2026)
- ✓ DELIVERED 14% TOP-LINE GROWTH Y-O-Y IN MARCH 2026

GEL MILLION

GEL MILLION



HEALTHCARE SERVICES BUSINESS PERFORMANCE OVERVIEW




HOSPITALS BUSINESS

KEY HIGHLIGHTS:


- ✓ Remarkable revenue growth of c.14% in 1Q26, mostly driven by outpatient services, which increased by c. 17% y-o-y in 1Q26
- ✓ Operating cash flow reflects seasonality patterns in state cash collections
- ✓ Average length of stay reduced by 0.5 days

OPERATING HIGHLIGHTS² - BED OCCUPANCY RATES (%)

Average length of stay (days)



NET REVENUE




WC/Revenue, % 23.9%

19.7%


EBITDA¹

EBITDA margin (excl. IFRS 16)




OPERATING CASH FLOWS¹

EBITDA to cash conversion (excl. IFRS 16)



HOSPITALS MARKET SHARES | NUMBER OF HOSPITAL BEDS*



*Total number of beds account to 16,062

HEALTHCARE SERVICES BUSINESS PERFORMANCE OVERVIEW (CONT'D)




CLINICS & DIAGNOSTICS

KEY HIGHLIGHTS:


- ✓ Number of tests performed in our diagnostics business increased by 3.3% in 1Q26 (y-o-y)
- ✓ Net revenue grew by 13.9% y-o-y in 1Q26 (y-o-y)
- ✓ EBITDA growth in 1Q26 comprised 28.3% (y-o-y)

OPERATING HIGHLIGHTS


NUMBER OF ADMISSIONS (THOUSANDS) - POLYCLINICS



NUMBER OF TESTS PERFORMED (MILLION) - DIAGNOSTICS




NET REVENUE




EBITDA¹

EBITDA margin (excl. IFRS 16)




OPERATING CASH FLOWS¹

EBITDA to cash conversion (excl. IFRS 16)



CLINICS MARKET SHARES | NUMBER OF REGISTERED PATIENTS



*Total number of registered patients account to 3,113,453



HEALTHCARE SERVICES BUSINESS KEY CONSIDERATIONS

1

EXPANDED MEDICAL INFRASTRUCTURE, STRENGTHENED CLINICAL TEAMS AND LEADERSHIP, AND ADDED NEW SERVICES ACROSS SEVERAL REGIONS

2

DELIVERED 14% Y-O-Y TOP-LINE GROWTH IN 1Q26

3

NET DEBT TO EBITDA (EXCL. IFRS 16) DECLINING FROM 4.1X IN MARCH 2025 TO 3.7X IN MARCH 2026